Efficacy of bendamustine in relapsed/refractory myeloma patients: Results from the French compassionate use program

Leukemia and Lymphoma

Volumn 53, Issue 4, 2012, Pages 632-634

  Damaj, G ^a   Malard, F ^b   Hulin, C ^c   Caillot, D ^d   Garidi, R ^e   Royer, B ^a   Marit, G ^f   Stoppa, A M ^g   Banos, A ^e   Morineau, N ^h   Moreau, P ^i,k   Fitoussi, O ^j   Tiab, M ^e  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d DIJON UNIVERSITY HOSPITAL   (France)

^e CENTRE HOSPITALIER   (France)

^f BORDEAUX UNIVERSITY HOSPITAL   (France)

^g INSTITUT PAOLI CALMETTES   (France)

^h Hématologie   (France)

ⁱ Centre Hospitalier de Lorient   (France)

^j Hematology Departments of Angers   (France)

^k HÔTEL DIEU   (France)

more..

Author keywords

Bendamustine; Chemotherapeutic approaches; Myeloma

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; ELOTUZUMAB; LENALIDOMIDE; MELPHALAN; POMALIDOMIDE; PREDNISONE; SALINOSPORAMIDE A; STEROID; THALIDOMIDE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RELAPSE; COHORT ANALYSIS; COMPASSIONATE USE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

EID: 84859013389     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.622422     Document Type: Article

References (14)

1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
2. Lonial S. Relapsed multiple myeloma. Hematology Am Soc Hematol Educ Program 2010;2010:303-309.
3. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009;27:1492-1501.
4. Strumberg D, Harstrick A, Doll K, et al. Bendamustine hydrochloride activity against doxorubicinresistant human breast carcinoma cell lines. Anticancer Drugs 1996;7:415-421.
5. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008;14:309-317.
6. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-1123.
7. Knop S, Straka C, Haen M, et al. Th e effi cacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005;90:1287-1288.
8. Pönisch W, Rozanski M, Goldschmidt H, et al. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. Br J Haematol 2008;143:191-200.
9. Fenk R, Michael M, Zohren F, et al. Escalation therapy with bortezomib, dexamethasone, and bendamustine for patients with relapsed or refractory myeloma. Leuk Lymphoma 2007;48: 2345-2351.
10. Schey S, Ramasamy K, Hazel B, et al. Bendamustine is a well tolerated and eff ective therapy for multiple myeloma patients with renal impairment. Haematologica 2011;96(s1):S115 (P-285).
11. Cheson BD, Wendtner CM, Pieper A, et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 2010;10:21-27.
12. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide and lowdose dexamethasone is active and well tolerated in lenalidomide refractory multiple myeloma. Leukemia 2010;24:1934-1939.
13. Siegel D, Wang L, Orlowski RZ, et al. PX-171 - 004, an ongoing open-label, phase II study of single-agent carfi lzomib (CFZ) in patients with relapsed or refractory myeloma (MM); updated results from the bortezomib-treated cohort. Bloo d (ASH Annual Meeting Abstracts) 2009;114:303.
14. Kumar S, Blade J, Crowley J, et al. Natural history of multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Blood (ASH Annual Meeting Abstracts) 2009;114:2878.